bioRxiv preprint doi: https://doi.org/10.1101/2020.02.28.969485; this version posted February 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models Fabio Henrique Brasil da Costa1,2, Michael Lewis3, Anna Truong4, Daniel Carson1,5, Mary Farach-Carson1,2,6,¤,* 1 Biosciences Department, Rice University, Houston, TX, USA 2 Department of Diagnostic and Biomedical Sciences, The University of Texas Health Science Center School of Dentistry, Houston, TX, USA 3 Department of Pathology and Medicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA 4 Department of Chemistry, Rice University, Houston, TX, USA 5 Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 6 Department of Bioengineering, Rice University, Houston, TX, USA ¤Current Address: Department of Diagnostic and Biomedical Sciences, The University of Texas Health Science Center School of Dentistry, Houston, TX, USA *
[email protected] Abstract Bone marrow stroma influences metastatic prostate cancer (PCa) progression, latency, and recurrence. At sites of PCa bone metastasis, cancer-associated fibroblasts and tumor-associated macrophages interact to establish a perlecan-rich desmoplastic stroma. As a heparan sulfate proteoglycan, perlecan (HSPG2 ) stores and stabilizes growth factors, including heparin-binding Wnt3A, a positive regulator of PCa cell growth. Because PCa cells alone do not induce CAF production of perlecan in the desmoplastic stroma, we sought to discover the sources of perlecan and its growth factor-releasing modifiers SULF1, SULF2, and heparanase in PCa cells and xenografts, bone marrow fibroblasts, and macrophages.